Table 1.
A summary of the pooled comparative analyses of biologic drug survival.
| Pairwise comparisons | SEC vs. ADA | SEC vs. ETA | SEC vs. INF | SEC vs. IXE | SEC vs UST | |
|---|---|---|---|---|---|---|
| 1 year | ||||||
| Pooled HR | 0.99 (0.70–1.40) | 1.10 (0.90–1.35) | 1.07 (0.85–1.36) | 2.01 (1.09–3.71) | 0.62 (0.47–0.81) | |
| Superior biologic | ND | ND | ND | SEC | UST | |
| Pairwise comparisons | UST vs. ADA | UST vs. ETA | UST vs. INF | ADA vs. ETA | ADA vs. INF | ETA vs. INF |
| 2 years | ||||||
| Pooled HR | 1.92 (1.61–2.29) | 2.28 (1.92–2.70) | 2.24 (1.92–2.60) | 1.13 (0.99–1.30) | 1.32 (1.06–1.63) | 1.19 (0.98–1.45) |
| Superior biologic | UST | UST | UST | ND | ADA | ND |
| 5 years | ||||||
| Pooled HR | 1.48 (1.33–1.65) | 1.97 (1.68–2.31) | 2.04 (1.75–2.38) | 1.31 (1.12–1.54) | 1.72 (1.52–2.02) | 1.40 (1.17–1.69) |
| Superior biologic | UST | UST | UST | ADA | ADA | ETA |
Analyses were completed when there was sufficient data. UST, ustekinumab; ADA, adalimumab; INF, infliximab; HR, hazard ratio; ND, no difference; vs., versus.